{"product_id":"vvos-pestle-analysis","title":"(VVOS) Vivos Therapeutics, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Vivos Therapeutics, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why those factors matter to strategy and investment. The page shows a real preview of the report so you can judge style and depth before buying; purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. healthcare reimbursement policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. payer policy shapes Vivos Therapeutics, Inc.’s adult OSA and snoring market because coverage often depends on a sleep study and proof of severity; Medicare covers CPAP when AHI is 15+ or 5 to 14 with symptoms or comorbidities. That makes physician referrals and patient uptake sensitive to reimbursement rules. When non-surgical options lack clear coverage, adoption slows and out-of-pocket costs rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanada provincial health system exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. sells in Canada and the United States, but Canada’s 13 provincial and territorial health systems can change how fast sleep-screening and oral-appliance care spreads. Provincial funding rules and referral pathways can speed adoption in one province and slow it in another, so clinic uptake is uneven. That matters because even small policy shifts can move sales timing and order volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState and provincial dental practice oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. sells mainly through licensed dentists, so state and provincial dental boards matter. In the U.S., 50 state boards plus the District of Columbia set scope-of-practice rules, which can change how treatment protocols are delivered, advertised, and supervised. That makes local compliance a clinic-by-clinic requirement, not a one-time national check.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health attention on sleep disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eObstructive sleep apnea affects an estimated 30 million U.S. adults, yet only about 6 million are diagnosed, so public health campaigns can still widen screening and treatment access. Medicare spent over $1.6 trillion in fiscal 2024, and policy pressure to cut downstream costs supports earlier detection of sleep disorders. For Vivos Therapeutics, Inc., more awareness can lift demand for screening and care programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge undiagnosed market\u003c\/li\u003e\n\u003cli\u003ePolicy supports early diagnosis\u003c\/li\u003e\n\u003cli\u003eAwareness can boost treatment demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCross-border medical device trade rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. sells in the U.S. and Canada, so cross-border device rules can slow shipments and raise landed costs. The U.S.-Canada trade lane is huge, with about US$1.3 trillion in annual goods trade, so even small customs or labeling changes can affect distributor timing. A policy shift by FDA, Health Canada, or under USMCA can push revenue recognition into later quarters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBorder checks can delay shipments.\u003c\/li\u003e\n\u003cli\u003eImport rules raise landed costs.\u003c\/li\u003e\n\u003cli\u003ePolicy changes can shift revenue timing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy and Coverage Shape Vivos’ OSA Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. depends on U.S. and Canadian health policy because adult OSA coverage, referral rules, and dental scope laws shape who gets treated and when. Medicare still covers CPAP only with AHI 15+ or 5 to 14 plus symptoms, so reimbursement can slow non-surgical adoption. Public screening support matters too, since about 30 million U.S. adults have OSA and only about 6 million are diagnosed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003eMedicare AHI 15+ or 5-14 + symptoms\u003c\/td\u003e\n\u003ctd\u003eAdoption timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket gap\u003c\/td\u003e\n\u003ctd\u003e30M vs 6M diagnosed\u003c\/td\u003e\n\u003ctd\u003eScreening upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines Vivos Therapeutics, Inc. through Political, Economic, Social, Technological, Environmental, and Legal forces shaping its market and strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, clear PESTLE snapshot of Vivos Therapeutics, Inc. that helps teams spot external risks and opportunities fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, clinical studies, SEC filings, and trusted benchmarks to let investors quickly verify Vivos Therapeutics’ market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscretionary spending on elective therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. sells a non-invasive, non-surgical therapy, but elective care still depends on what patients must pay themselves. In the U.S., out-of-pocket health spending was about 10% of total personal health care spending, so reimbursement gaps can matter. When household budgets tighten and insurance coverage is limited, demand for discretionary therapies can soften fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation in healthcare operating costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflation is pressuring Vivos Therapeutics, Inc. customers through higher clinic rent, labor, and supply costs; U.S. medical care prices were still rising in 2025, keeping budgets tight. Providers facing 5%+ wage gains in many health roles and pricier testing inputs may delay new programs. That can slow adoption of the Vivos System and VivoScore Program, especially where price sensitivity is high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-cap medtech financing conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc., founded in 2016, depends on capital access to fund marketing, product development, and commercialization. In a tighter small-cap medtech market, higher borrowing costs raise the hurdle for equity and debt raises, so growth spending can slow fast. With the Fed funds rate still in restrictive territory in 2025-2026, financing stays a key pressure point for smaller medtech names.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInsurance coverage variability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInsurance coverage for sleep apnea testing and oral treatment is uneven across payers, so Vivos Therapeutics, Inc. can face slower patient conversion when approval is uncertain. This matters because sleep apnea affects about 25 million U.S. adults, but reimbursement rules still differ on home tests, sleep studies, and device coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUneven coverage slows treatment starts\u003c\/li\u003e\n\u003cli\u003eReimbursement risk hits clinic margins\u003c\/li\u003e\n\u003cli\u003eProviders want payment certainty first\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. and Canada revenue concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. relies mainly on the United States and Canada, so revenue is tied to two closely linked markets. That concentration means a regional slowdown, weaker consumer spending, or lower elective health-care demand can hit sales fast, while a stronger U.S. dollar can also trim Canada results when translated back into Company Name reporting currency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh U.S. and Canada mix raises slowdown risk.\u003c\/li\u003e\n\u003cli\u003eDemand swings in both markets move results quickly.\u003c\/li\u003e\n\u003cli\u003eCurrency shifts can distort Canada revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Faces Tight Budgets, Higher Costs, and Slower Rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. faces demand tied to elective spend: U.S. out-of-pocket health spending is about 10% of total personal health care spending, so tight budgets can slow starts. Higher 2025 medical wages and clinic costs also squeeze provider margins. Restrictive 2025-2026 rates make funding sales and rollout harder.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eReimbursement\u003c\/td\u003e\n\u003ctd\u003eSleep apnea impacts ~25M U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eVivos Therapeutics, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Vivos Therapeutics, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use, with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult OSA and snoring demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdult obstructive sleep apnea and snoring address a huge, underdiagnosed market: the American Academy of Sleep Medicine estimates nearly 1 billion adults worldwide have OSA, and about 80% remain undiagnosed. As social awareness rises, more adults seek screening and treatment for poor sleep, loud snoring, and daytime fatigue. That shift can lift demand for Vivos Therapeutics, Inc.’s adult-focused oral appliance care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreference for non-invasive care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. fits a clear patient shift toward care that is non-invasive, non-surgical, and drug-free. That matters because many people want to avoid the recovery time, risks, and repeat use tied to surgery or long-term medication. This preference keeps demand open for alternative treatment paths like the Vivos System.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome sleep testing convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivoScore’s home sleep tests for adults and children reduce the hassle of lab visits, which can lift screening completion and speed earlier diagnosis. In the U.S., sleep apnea is still heavily missed, with about 80% of moderate to severe cases undiagnosed, so easier at-home testing can matter.\u003c\/p\u003e\n\u003cp\u003eThat convenience also fits family routines better, which can help more people finish testing after symptoms first appear. For Vivos Therapeutics, Inc., this can support higher patient engagement and broader addressable screening reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStigma around sleep and airway problems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSleep apnea is often underreported because people normalize snoring, fatigue, and poor sleep. About 80% of obstructive sleep apnea cases stay undiagnosed, so stigma can delay care until work, mood, and daily life suffer. Dentist-led screening and sleep-professional education can raise acceptance of treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e80% of cases go undiagnosed\u003c\/li\u003e\n\u003cli\u003eStigma delays care\u003c\/li\u003e\n\u003cli\u003eEducation improves acceptance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDentist-led patient screening behavior\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. relies on licensed dentists, so adoption is shaped by chairside screening habits and referral trust. Routine cleanings and exams give general dentists repeated patient touchpoints, making them a high-frequency screening channel for sleep-disordered breathing. In this model, provider awareness often matters as much as product fit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDentists control first screening.\u003c\/li\u003e\n\u003cli\u003eRoutine visits create repeat touchpoints.\u003c\/li\u003e\n\u003cli\u003eReferral behavior drives conversion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Benefits as OSA Awareness and Non-Invasive Care Grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociological demand for Vivos Therapeutics, Inc. is supported by stigma, poor sleep awareness, and a clear shift toward non-invasive care. With about 1 billion adults worldwide affected by OSA and roughly 80% undiagnosed, social acceptance of screening and dentist-led referrals can drive earlier diagnosis and treatment uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOSA burden\u003c\/td\u003e\n\u003ctd\u003e~1B adults worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndiagnosed rate\u003c\/td\u003e\n\u003ctd\u003e~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCare preference\u003c\/td\u003e\n\u003ctd\u003eNon-invasive, drug-free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos System multi-disciplinary therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos System’s multi-disciplinary therapy blends dental device design with sleep medicine, targeting adult dentofacial abnormalities, obstructive sleep apnea, and snoring. The market need is large: about 425 million adults aged 30-69 worldwide are estimated to have moderate-to-severe OSA, so clinical performance matters. Product edge depends on repeatable outcomes, shorter treatment workflows, and provider adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivoScore home sleep testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivoScore gives Vivos Therapeutics, Inc. a tech-enabled screening and home sleep testing line for adults and children, so the company can support diagnosis as well as treatment. Home sleep apnea testing can cut the need for in-lab visits and speed triage, which matters in a market where obstructive sleep apnea affects an estimated 1 billion people worldwide.\u003c\/p\u003e\n\u003cp\u003eThis remote model can widen access, lower friction for patients, and feed more leads into the treatment funnel. It also fits the shift toward telehealth and at-home diagnostics, where the value is in fast, data-based testing without a clinic stay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital screening and patient workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDigital intake and remote sleep data can cut screening friction for Vivos Therapeutics, Inc., since up to 80% of obstructive sleep apnea cases are still undiagnosed. Workflow tools let providers review more cases with fewer visits, which matters in a market where time and chair capacity are tight.\u003c\/p\u003e\n\u003cp\u003eBetter system links can also lift conversion from screening to treatment by reducing drop-off between first contact and diagnosis. For Vivos Therapeutics, Inc., that can mean faster case review, cleaner referrals, and more treated patients per clinic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProtocol personalization potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdult dentofacial patterns and sleep disorders vary a lot, so protocol personalization can improve fit and outcomes. With obstructive sleep apnea affecting about 1 billion adults worldwide, technology that maps anatomy and response supports individualized planning. In a multidisciplinary model, customization helps align dental, airway, and sleep care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferent anatomy needs different protocols\u003c\/li\u003e\n\u003cli\u003ePersonalized tech can lift outcomes\u003c\/li\u003e\n\u003cli\u003eMultidisciplinary care depends on customization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinic and telehealth interoperability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinic and telehealth interoperability matters for Vivos Therapeutics, Inc. because dentists and sleep specialists expect devices and services to slot into daily workflows. In 2025, U.S. telehealth use stayed mainstream, with about 12% of adults reporting a telehealth visit in the prior 12 months, so systems that connect to remote monitoring and clinical software are easier to adopt and cut admin friction.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eFits modern clinic workflows\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports telehealth adoption\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLowers admin burden for providers\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnected Sleep Care Could Boost Vivos’ Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. relies on tech that links airway screening, home sleep tests, and device-led treatment, so speed and data quality matter. With about 1 billion adults worldwide affected by obstructive sleep apnea and only about 12% of U.S. adults using telehealth in the last 12 months, connected workflows can lift access and adoption. Personalized protocols and clinic software integration can also cut drop-off between diagnosis and treatment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOSA market\u003c\/td\u003e\n\u003ctd\u003e~1 billion adults worldwide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth use\u003c\/td\u003e\n\u003ctd\u003e~12% of U.S. adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical device regulatory compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. operates in tightly regulated U.S. and Canadian device markets, so product claims, labeling, and clinical data must stay aligned with FDA and Health Canada rules. In the U.S., most medical devices move through the 510(k) path, while Canada requires device licensing before sale. Compliance is not optional; it is the gate to commercialization and ongoing market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed-professional distribution model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Vivos System is sold only through licensed medical professionals, mainly general dentists, so legality hinges on provider credentials and scope of practice. Training and usage controls help reduce compliance risk and limit misuse. This channel model also tightens oversight, which matters in a regulated medical device market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical claims and advertising scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClaims about OSA and snoring treatment must be tightly supported by clinical data, because U.S. ad rules can trigger FTC civil penalties of up to $53,088 per violation in 2025. For Vivos Therapeutics, Inc., how outcomes are worded to patients and providers matters as much as the data itself. Misleading or overstated claims can bring enforcement risk and damage trust fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHealth data privacy obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc.'s VivoScore uses home sleep tests and patient screening data, so health data privacy rules shape how it collects, stores, and shares protected health information. Under HIPAA, covered entities and business partners must keep safeguards in place and report breaches within 60 days. Strong data controls support trust and lower legal risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHome sleep data can be sensitive PHI.\u003c\/li\u003e\n\u003cli\u003eHIPAA drives storage and sharing rules.\u003c\/li\u003e\n\u003cli\u003eStrong controls protect trust and compliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability and informed consent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. faces product liability risk because medical and dental therapies can trigger claims if outcomes are poor or adverse events occur. Informed consent and tight documentation are key, since liability can hit both the Company and its provider network if records do not clearly show patient understanding and treatment steps.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLiability rises with adverse outcomes\u003c\/li\u003e\n\u003cli\u003eConsent forms must be clear\u003c\/li\u003e\n\u003cli\u003eRecords must prove delivery and follow-up\u003c\/li\u003e\n\u003cli\u003eProvider-network controls reduce exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos Faces Tight FDA, FTC, and HIPAA Legal Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for Vivos Therapeutics, Inc. is driven by device regulation, claim support, and patient data rules. U.S. and Canadian market access depends on device clearances and licensing, while any overstated OSA or snoring claim can trigger FTC penalties of up to $53,088 per violation in 2025.\u003c\/p\u003e\n\u003cp\u003eBecause the Vivos System is sold through licensed dentists, scope-of-practice and training controls matter. HIPAA also applies to sleep-test and patient data, with breach reports due within 60 days.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal point\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTC penalty per violation\u003c\/td\u003e\n\u003ctd\u003e$53,088\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA breach notice\u003c\/td\u003e\n\u003ctd\u003e60 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales channel\u003c\/td\u003e\n\u003ctd\u003eLicensed dentists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-surgical care lowers facility intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc.’s Vivos System is non-invasive and non-surgical, so it can avoid operating-room use and the energy, sterilization, and single-use supply load tied to surgery. Healthcare is a major emitter, at about 4.4% of global net emissions, so shifting care to lower-intensity outpatient treatment can trim footprint. That supports a lighter facility profile than surgery-based care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome sleep tests reduce patient travel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc.'s VivoScore includes home sleep testing, which can reduce repeat clinic trips for the estimated 30 million U.S. adults with sleep apnea. Fewer trips cut patient travel time and transportation emissions, while also easing scheduling and follow-up costs. That makes the model both greener and more efficient for care delivery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffice-based therapy uses less hospital infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. relies on licensed dentists for delivery, so most care happens in offices, not hospitals. That cuts dependence on inpatient beds, ORs, and high-energy clinical systems, which matters because U.S. health care drives about 8.5% of national greenhouse-gas emissions. Office-based therapy can use fewer resources and less energy than hospital-level care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePackaging and consumable waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. sells medical and dental devices, so shipping packs, inserts, and disposable parts add waste. In healthcare, about 85% of waste is non-hazardous and 15% is hazardous, so material choice matters for landfill and disposal costs.\u003c\/p\u003e\n\u003cp\u003eWaste cuts are now part of procurement screens, and suppliers with less packaging can win more orders. The U.S. healthcare system generates about 5.9 million tons of waste a year, so even small reductions can matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePackaging adds shipping waste\u003c\/li\u003e\n\u003cli\u003eDisposable parts raise impact\u003c\/li\u003e\n\u003cli\u003eLower waste helps procurement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain and manufacturing footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. relies on manufacturing and distribution networks, so energy use, sourcing, and freight all shape its environmental footprint. In 2025\/2026, supply chain resilience matters because any plant or shipping delay can disrupt service continuity across the U.S. and Canada.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing drives energy use and waste.\u003c\/li\u003e\n\u003cli\u003eSupplier sourcing affects footprint and risk.\u003c\/li\u003e\n\u003cli\u003eLogistics can slow device delivery.\u003c\/li\u003e\n\u003cli\u003eResilience protects U.S.-Canada continuity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivos' Noninvasive Care Can Shrink Sleep Apnea's Carbon Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVivos Therapeutics, Inc. has a lower-footprint model than surgery-based care: non-invasive treatment avoids OR energy, sterilization, and single-use surgical waste. U.S. health care drives about 8.5% of national greenhouse-gas emissions, so shifting care to dental offices can help cut emissions.\u003c\/p\u003e\n\u003cp\u003eHome sleep testing and fewer clinic trips also reduce travel emissions for the 30 million U.S. adults with sleep apnea. Packaging and disposable parts still add waste, but better sourcing can matter in a system that generates about 5.9 million tons of waste a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. health care emissions\u003c\/td\u003e\n\u003ctd\u003e8.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep apnea adults\u003c\/td\u003e\n\u003ctd\u003e30 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. health care waste\u003c\/td\u003e\n\u003ctd\u003e5.9 million tons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235158466825,"sku":"vvos-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/vvos-pestle-analysis.webp?v=1785735723","url":"https:\/\/dcfanalyst.com\/products\/vvos-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}